中华预防医学杂志
中華預防醫學雜誌
중화예방의학잡지
CHINESE JOURNAL OF
2013年
8期
731-735
,共5页
陈建国%陆卫中%朱源荣%张永辉%陆建华%陈陶阳
陳建國%陸衛中%硃源榮%張永輝%陸建華%陳陶暘
진건국%륙위중%주원영%장영휘%륙건화%진도양
肝肿瘤%肝硬化%高尔基体%肝炎表面抗原,乙型%时间序列
肝腫瘤%肝硬化%高爾基體%肝炎錶麵抗原,乙型%時間序列
간종류%간경화%고이기체%간염표면항원,을형%시간서렬
Liver neoplasm%Liver cirrhosis%Golgi apparatus%Hepatitis B surface antigens%Time series
目的 探讨肝癌发病前后高尔基体糖蛋白73 (GP73)的动态水平及相关因素.方法 2007至2012年对一组乙型肝炎表面抗原(HBsAg)阳性者人群开展一年两次的周期性的筛查,统一保留血标本于生物样本库,直至肝癌发生.将肝癌发病时及发病前30个月内6个时点中,至少有3次血标本并有B超临床检查结果的39例肝癌患者列为血清GP73检测分析对象,最终获得162个标本.采用双抗体夹心ELISA法检测GP73.用stata软件作时序间分析并进行不同分组间差异的统计学检验.结果 肝癌发病时的39例患者GP73检测值为(126.77±73.73)μg/L,发病前5次GP73检测的平均值分别为(128.32±81.18)、(129.97±83.62)、(127.38±80.10)、(135.52±97.88)及(138.24 ±93.58) μg/L,差异无统计学意义(F=0.07,P=0.997).39例肝癌发病前后的GP73水平未见明显的趋势变化.162个检测样本按B超检查结果划分为不伴有肝硬化(63例次)和伴有肝硬化(99例次)两组,GP73平均水平分别为(97.16 ±51.39)、(151.20 ±91.68) μg/L,差异有统计学意义(F=18.22,P＜0.01).进一步以GP73均值(130.19 μg/L)将调查对象分为两组,不伴有肝硬化者中只有1/14的患者GP73水平高于平均值,而伴有肝硬化者(25例)中有12例的GP73水平高于平均值,差异有统计学意义(P =0.013).拟合回归模型也显示GP73与时间序列不相关(t=0.75,P=0.455),而与肝硬化相关(t=4.30,P＜0.01).结论 肝癌患者发病时及发病前30个月内的GP73水平动态变化不大.肝癌患者GP73水平的高低是由肝病背景所决定的；肝硬化可能是一个主要的影响因素或混杂因素.
目的 探討肝癌髮病前後高爾基體糖蛋白73 (GP73)的動態水平及相關因素.方法 2007至2012年對一組乙型肝炎錶麵抗原(HBsAg)暘性者人群開展一年兩次的週期性的篩查,統一保留血標本于生物樣本庫,直至肝癌髮生.將肝癌髮病時及髮病前30箇月內6箇時點中,至少有3次血標本併有B超臨床檢查結果的39例肝癌患者列為血清GP73檢測分析對象,最終穫得162箇標本.採用雙抗體夾心ELISA法檢測GP73.用stata軟件作時序間分析併進行不同分組間差異的統計學檢驗.結果 肝癌髮病時的39例患者GP73檢測值為(126.77±73.73)μg/L,髮病前5次GP73檢測的平均值分彆為(128.32±81.18)、(129.97±83.62)、(127.38±80.10)、(135.52±97.88)及(138.24 ±93.58) μg/L,差異無統計學意義(F=0.07,P=0.997).39例肝癌髮病前後的GP73水平未見明顯的趨勢變化.162箇檢測樣本按B超檢查結果劃分為不伴有肝硬化(63例次)和伴有肝硬化(99例次)兩組,GP73平均水平分彆為(97.16 ±51.39)、(151.20 ±91.68) μg/L,差異有統計學意義(F=18.22,P＜0.01).進一步以GP73均值(130.19 μg/L)將調查對象分為兩組,不伴有肝硬化者中隻有1/14的患者GP73水平高于平均值,而伴有肝硬化者(25例)中有12例的GP73水平高于平均值,差異有統計學意義(P =0.013).擬閤迴歸模型也顯示GP73與時間序列不相關(t=0.75,P=0.455),而與肝硬化相關(t=4.30,P＜0.01).結論 肝癌患者髮病時及髮病前30箇月內的GP73水平動態變化不大.肝癌患者GP73水平的高低是由肝病揹景所決定的；肝硬化可能是一箇主要的影響因素或混雜因素.
목적 탐토간암발병전후고이기체당단백73 (GP73)적동태수평급상관인소.방법 2007지2012년대일조을형간염표면항원(HBsAg)양성자인군개전일년량차적주기성적사사,통일보류혈표본우생물양본고,직지간암발생.장간암발병시급발병전30개월내6개시점중,지소유3차혈표본병유B초림상검사결과적39례간암환자렬위혈청GP73검측분석대상,최종획득162개표본.채용쌍항체협심ELISA법검측GP73.용stata연건작시서간분석병진행불동분조간차이적통계학검험.결과 간암발병시적39례환자GP73검측치위(126.77±73.73)μg/L,발병전5차GP73검측적평균치분별위(128.32±81.18)、(129.97±83.62)、(127.38±80.10)、(135.52±97.88)급(138.24 ±93.58) μg/L,차이무통계학의의(F=0.07,P=0.997).39례간암발병전후적GP73수평미견명현적추세변화.162개검측양본안B초검사결과화분위불반유간경화(63례차)화반유간경화(99례차)량조,GP73평균수평분별위(97.16 ±51.39)、(151.20 ±91.68) μg/L,차이유통계학의의(F=18.22,P＜0.01).진일보이GP73균치(130.19 μg/L)장조사대상분위량조,불반유간경화자중지유1/14적환자GP73수평고우평균치,이반유간경화자(25례)중유12례적GP73수평고우평균치,차이유통계학의의(P =0.013).의합회귀모형야현시GP73여시간서렬불상관(t=0.75,P=0.455),이여간경화상관(t=4.30,P＜0.01).결론 간암환자발병시급발병전30개월내적GP73수평동태변화불대.간암환자GP73수평적고저시유간병배경소결정적；간경화가능시일개주요적영향인소혹혼잡인소.
Objective To observe the dynamic levels of serum Golgi protein 73 (GP73) in patients prior to and after the onset of liver cancer,and to explore the related factors.Methods From 2007 to 2012,a periodical screening program was carried out in a group of high risk population with positive Hepatitis B surface antigens (HBsAg),twice a year.Their serum specimens from every screening time point were kept in Qidong Biobank until liver cancer was diagnosed.Thirty-nine patients with liver cancer were recruited for the study,each of them at least had three times of specimens collected as well as B untrasound scan (BUS) exam results at onset of disease and within 30 months before diagnosed,amongst 6 time points.In total,there were 162 specimens collected to test GP73 by double-antibody sandwich enzyme-linked immuno-sorbent assay (ELISA).Statistical analyses of time series and differences among groups were performed by stata software 10.Results The average value of 39 patient's GP73 at the time point of liver cancer onset was (126.77 ±73.73) μg/L,while the values at the other five time points prior to the onset were (128.32 ±81.18),(129.97 ± 83.62),(127.38 ± 80.10),(135.52 ± 97.88) and (138.24 ± 93.58) μg/L,respectively,with no significant difference (F =0.07,P =0.997).No obvious changing trends of GP73 were observed among the 39 liver cancer cases at the 6 time points.All 162 samples were divided into two groups:without hepatic cirrhosis (63 samples) and with cirrhosis (99 samples) according to findings of B-ultrasonic wave; whose average GP73 values were separately (97.16 ± 51.39) and (151.20 ±91.68) μg/L.The difference showed statistical significance (F =18.22,P ＜ 0.01).Furthermore,if we grouped the samples by the average value of GP73 at 130.19 μg/L,then there were only 1/14 of the subjects without hepatic cirrhosis having higher GP73 values,but 12 of the 25 subjects with hepatic cirrhosis having higher GP73 values.The difference showed statistical significance (P =0.013).The results of Linear regression model also showed that there was no correlation between GP73 and time series (t =0.75,P =0.455),but significant correlation between GP73 and hepatic cirrhosis (t =4.30,P ＜ 0.01).Conclusion No significant changes of the dynamic levels of GP73 could be found among the liver cancer patients within 30 months prior to the onset of disease.GP73 values of the patients with liver cancer may depend on their background of hepatic diseases ; and hepatic cirrhosis might be one of the main influencing factors or confounding factors.
